Related content

Fosaprepitant-induced phlebitis: a focus on patients receiving doxorubicin/cyclophosphamide therapy

By Leal A.   Kadakia K.   Looker S.   Hilger C.   Sorgatz K.   Anderson K.   Jacobson A.   Grendahl D.   Seisler D.   Hobday T.   Loprinzi Charles  

Supportive Care in Cancer, Vol. 22, Iss. 5, 2014-05 ,pp. : 1313-1317

Springer Publishing Company

Access to resources Recommend Favorite

Feasibility study of oral cyclophosphamide salvage therapy for the treatment of heavily pretreated patients with recurrent epithelial ovarian cancer

By Watanabe Yoh   Etoh Tomomaro   Koike Eiji   Mizuno Yoshiaki   Wang Wei-Min   Hoshiai Hiroshi  

International Journal of Clinical Oncology, Vol. 15, Iss. 5, 2010-10 ,pp. : 468-471

Springer Publishing Company

Access to resources Recommend Favorite

Use of liposomal doxorubicin–cyclophosphamide combination in breast cancer patients with brain metastases: a monocentric retrospective study

By Linot B.   Campone M.   Augereau P.   Delva R.   Abadie-Lacourtoisie S.   Nebout-Mesgouez N.   Capitain O.  

Journal of Neuro-Oncology, Vol. 117, Iss. 2, 2014-04 ,pp. : 253-259

Springer Publishing Company

Access to resources Recommend Favorite

Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients

By Loos Walter   Wit Ronald   Freedman Steven   Dyck Kristien   Gambale Jay   Li Susie   Murphy Gail   Noort Connie   Bruijn Peter   Verweij Jaap  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 3, 2007-03 ,pp. : 407-412

Springer Publishing Company

Access to resources Recommend Favorite

Surgical considerations for breast cancer patients receiving neoadjuvant systemic therapy

By Hunt Kelly K   Mittendorf Elizabeth A  

Breast Cancer Management, Vol. 2, Iss. 5, 2013-09 ,pp. : 385-395

Future Medicine

Access to resources Recommend Favorite